Cargando…
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Neuroblastoma (NB) is a pediatric cancer of the sympathetic nervous system which accounts for 8% of childhood cancers. Most NBs express high levels of the disialoganglioside GD2. Several antibodies have been developed to target GD2 on NB, including the human/mouse chimeric antibody ch14.18, known as...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306059/ https://www.ncbi.nlm.nih.gov/pubmed/30613134 http://dx.doi.org/10.2147/BTT.S114530 |